Patents by Inventor Carmen Alvarez
Carmen Alvarez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230390442Abstract: A system for implantation by sterilisation techniques. A sterile implantation system comprising a heat-sensitive polymeric matrix that modifies its structure in the presence of a compressed gas or supercritical fluid to produce a solid or semi-solid with porosity greater than 60%.Type: ApplicationFiled: October 22, 2021Publication date: December 7, 2023Inventors: Carlos Alberto Garcia Gonzalez, Víctor Santos Rosales, Maria Beatriz Magariños Ferro, Carmen Alvarez Lorenzo
-
Patent number: 11497810Abstract: A system for administering biologically active substances produced by foaming techniques using compressed gases or supercritical fluids relates to a porous system containing biologically active substances. The system includes a polymer matrix of poly(D,L-lactic-co-glycolic acid) or a polymer mixture containing poly(D,L-lactic-co-glycolic acid) of an intrinsic viscosity of less than 0.5 dL/g with other biodegradable synthetic or semisynthetic polyesters, a release-regulating component (starch and derivatives), and at least one biologically active substance. The matrix is biodegradable with a solid or semisolid consistency and a homogeneous appearance. A method for producing these systems using foaming with compressed fluids, and the use for the production of implants and scaffolds having this system are also disclosed. Optionally, a porogenic agent can be used for the formation of macropores by thermal decomposition.Type: GrantFiled: July 12, 2016Date of Patent: November 15, 2022Assignee: UNIVERSIDADE DE SANTIAGO DE COMPOSTELAInventors: Carlos Garcia Gonzalez, Luis A Diaz Gomez, Carmen Alvarez Lorenzo, Angel J Concheiro Nine
-
Publication number: 20190046627Abstract: The present invention relates to the use of a GNP-LLO91-99 complex for providing immune responses for the treatment or prophylaxis of cancer.Type: ApplicationFiled: February 23, 2017Publication date: February 14, 2019Inventors: Carmen ÁLVAREZ DOMÍNGUEZ, Ricardo CALDERÓN GONZÁLEZ, Elisabet FRANDE CABANES, Sonsoles YÁÑEZ DIAZ, Eva FERRÁNDEZ FERNÁNDEZ, Soledad PENADÉS ULLATE, Marco MARRADI, Isabel GARCÍA MARTÍN, Fernando RIVERA HERRERO
-
Publication number: 20180236086Abstract: A system for administering biologically active substances produced by foaming techniques using compressed gases or supercritical fluids relates to a porous system containing biologically active substances. The system includes a polymer matrix of poly(D,L-lactic-co-glycolic acid) or a polymer mixture containing poly(D,L-lactic-co-glycolic acid) of an intrinsic viscosity of less than 0.5 dL/g with other biodegradable synthetic or semisynthetic polyesters, a release-regulating component (starch and derivatives), and at least one biologically active substance. The matrix is biodegradable with a solid or semisolid consistency and a homogeneous appearance. A method for producing these systems using foaming with compressed fluids, and the use for the production of implants and scaffolds having this system are also disclosed. Optionally, a porogenic agent can be used for the formation of macropores by thermal decomposition.Type: ApplicationFiled: July 12, 2016Publication date: August 23, 2018Applicant: UNIVERSIDADE DE SANTIAGO DE COMPOSTELAInventors: Carlos GARCIA GONZALEZ, Luis A DIAZ GOMEZ, Carmen ALVAREZ LORENZO, Angel J CONCHEIRO NINE
-
Publication number: 20160194274Abstract: The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spinocerebellar Ataxia Type 3, Fragile-X-Associated Tremor/Ataxia Syndrome, Frontotemporal Degeneration/Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia Type 31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents. Therefore, this invention may be included either in the whole pharmaceutical or medical field.Type: ApplicationFiled: December 13, 2013Publication date: July 7, 2016Inventors: Irma GARCÍA ALCOVER, Arturo LÓPEZ CATEL, María del Carmen ÁLVAREZ ABRIL, Jose Rubén TORMO BELTRÁN, Manuel PÉREZ ALONSO, Rubén ARTERO ALLEPUZ, Diego Miguel CORTÉS MARTÍNEZ
-
Patent number: 8951548Abstract: The invention relates to acrylic hydrogels with pendant cyclodextrins, the preparation and application thereof as release systems and components of contact lenses. The method for obtaining acrylic hydrogels with pendant cyclodextrins is characterized in that the hydrogels are formed by a polymer lattice obtained by polymerization of mono- and bifunctional acrylic or methacrylic monomers and monomers having glycidyl groups in their structure, to which cyclodextrin units are covalently bound once formed; and the use and applications of the compositions in the preparation of contact lenses with the capacity for incorporating drugs, active substances or demulcents useful in the treatment of pathological or physiological conditions, in the production of topical, transdermal or transmucosal release systems for medicinal products or active substances, and in the preparation of cosmetics.Type: GrantFiled: August 4, 2009Date of Patent: February 10, 2015Assignee: Universidade de Santiago de CompostelaInventors: Carmen Alvarez Lorenzo, José Fernando Rosa Dos Santos, Juan José Torres Labandeira, Angel Concheiro Nine
-
Publication number: 20130156724Abstract: The invention describes for first time the activity of poloxamines as inducers in the differentiation of mesenchymal or progenitor cells. In particular, the invention demonstrates that poloxamines have an osteogenic ability. The invention relates to the use of one or more poloxamines or a pharmaceutical composition comprising same for the preparation of a drug for treting patients with bone defects in general. The invention also relates to a method for inducing the differentiation of mesenchymal or progenitor cells into osteoblasts by bringing said cells into contact with a sterilised aqueous dispersion or solution of one or more poloxamines.Type: ApplicationFiled: May 12, 2011Publication date: June 20, 2013Applicant: UNIVERSIDADE DE SANTIAGO DE COMPOSTELAInventors: Carmen Alvarez Lorenzo, Ana Rey Rico, Teresa Silva Rivera, José Couceiro Follente, Angel Concheiro Nine
-
Publication number: 20110200661Abstract: The invention relates to acrylic hydrogels with pendant cyclodextrins, the preparation and application thereof as release systems and components of contact lenses. The method for obtaining acrylic hydrogels with pendant cyclodextrins is characterized in that the hydrogels are formed by a polymer lattice obtained by polymerization of mono- and bifunctional acrylic or methacrylic monomers and monomers having glycidyl groups in their structure, to which cyclodextrin units are covalently bound once formed; and the use and applications of the compositions in the preparation of contact lenses with the capacity for incorporating drugs, active substances or demulcents useful in the treatment of pathological or physiological conditions, in the production of topical, transdermal or transmucosal release systems for medicinal products or active substances, and in the preparation of cosmetics.Type: ApplicationFiled: August 4, 2009Publication date: August 18, 2011Applicant: UNIVERSIDADE DE SANTIAGO DE COMPOSTELAInventors: Carmen Alvarez Lorenzo, José Fernando Rosa Dos Santos, Juan José Torres Labandeira, Angel Concheiro Nine
-
Publication number: 20090214604Abstract: The invention relates to a method of obtaining hydrogels based on (i) cyclodextrins, (ii) cyclodextrins and cellulose ethers or (iii) cyclodextrins and guar gum or the derivatives of same, using molecules containing two or more glycidyl ether groups in the structure thereof as a cross-linking agent. The invention also relates to the compositions thus obtained, which can include active substances and pharmaceuticals and which form inclusion complexes with cyclodextrins. The invention further relates to the use of same as components of controlled-release devices, such as transdermal pharmaceutical forms, vaginal, otic, ocular, rectal, oral or buccal transmucosal forms and parenteral implants, which are designed to administer active substances or pharmaceuticals to humans, animals or plants, or as components of cosmetic formulations.Type: ApplicationFiled: February 15, 2006Publication date: August 27, 2009Applicant: Universidade De Santiago De CompostelaInventors: Carmen Alvarez Lorenzo, Carmen Rodriguez-Tenreiro Sanchez, Juan Jose Torres Labandeira, Angel Concheiro Nine
-
Publication number: 20080050384Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.Type: ApplicationFiled: April 20, 2007Publication date: February 28, 2008Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Ronald Doll, Viyyoor Girijavallabhan, Alan Mallams, Carmen Alvarez, Kartik Keertikar, Jocelyn Rivera, Tin-Yau Chan, Vincent Madison, Thierry Fischmann, Lawrence Dillard, Vinh Tran, Zhenmin He, Ray James, Haengsoon Park, Vidyadhar Paradkar, Douglas Hobbs, Paul Kirschmeier, Rajat Bannerji
-
Publication number: 20070083044Abstract: In its many embodiments, the present invention provides a novel class of amino-substituted pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.Type: ApplicationFiled: October 4, 2006Publication date: April 12, 2007Inventors: Kamil Paruch, Timothy Guzi, Michael Dwyer, Carmen Alvarez
-
Publication number: 20070054925Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.Type: ApplicationFiled: March 31, 2006Publication date: March 8, 2007Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Ronald Doll, Viyyoor Girijavallabhan, Alan Mallams, Carmen Alvarez, Kartik Keertikar, Jocelyn Rivera, Tin-Yau Chan, Vincent Madison, Thierry Fischmann, Lawrence Dillard, Vinh Tran, Zhen He, Ray James, Haengsoon Park, Vidyadhar Paradkar, Douglas Hobbs
-
Publication number: 20070054906Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.Type: ApplicationFiled: March 31, 2006Publication date: March 8, 2007Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Ronald Doll, Viyyoor Girijavallabhan, Alan Mallams, Carmen Alvarez, Kartik Keertikar, Jocelyn Rivera, Tin-Yau Chan, Vincent Madison, Thierry Fischmann, Lawrence Dillard, Vinh Tran, Zhen He, Ray James, Haengsoon Park, Vidyadhar Paradkar, Douglas Hobbs
-
Publication number: 20070037824Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.Type: ApplicationFiled: September 3, 2003Publication date: February 15, 2007Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Ronald Doll, Viyyoor Girijavallabhan, Alan Mallams, Carmen Alvarez, Kartik Keertikar, Jocelyn Rivera, Tin-Yau Chan, Vincent Madison, Thierry Fischmann, Lawrence Dillard, Vinh Tran, Zhen He, Ray James, Haengsoon Park, Vidyadhar Paradkar, Douglas Hobbs
-
Publication number: 20060178371Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.Type: ApplicationFiled: March 31, 2006Publication date: August 10, 2006Inventors: Timothy Guzi, Kamil Paruch, Michael Dwyer, Ronald Doll, Viyyoor Girijavallabhan, Carmen Alvarez, Tin-Yau Chan, Chad Knutson, Vincent Madison, Thierry Fischmann, Lawrence Dillard, Vinh Tran, Zhen He, Ray James, Haengsoon Park
-
Patent number: 6740661Abstract: Disclosed are compounds of the formula: wherein R13 represents an imidazole ring; R14 represents a carbamate, urea, amide or sulfonamide group; R8 represents H when the alkyl chain between the amide group and the R13 imidazole group is substituted, or R8 represents a substituent such as arylalkyl, heteroarylalkyl or cycloalkyl; and the remaining substituents are as defined herein. Also disclosed are compounds wherein R8 is H, and the alkyl chain between the amide group and the R13 imidazole group is unsubstituted. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.Type: GrantFiled: December 20, 2001Date of Patent: May 25, 2004Assignee: Schering CorporationInventors: Arthur G. Taveras, Ronald J. Doll, Alan B. Cooper, Johan A. Ferreira, Timothy Guzi, Alan K. Mallams, Dinanath F. Rane, Viyyoor M. Girijavallabhan, Adriano Afonso, Cynthia J. Aki, Jianping Chao, Carmen Alvarez, Joseph M. Kelly, Tarik Lalwani, Jagdish A. Desai, James J-S Wang, Jay Weinstein
-
Patent number: 6440974Abstract: Novel compounds of the formula: are disclosed. In Formula 1.0 a represents N or NO, R1 and R3 are halo, R2 and R4 are independently H or halo provided that at least one is H, X is C, CH or N, and T represents a five or six membered heterocycloalkyl ring having one or two heteroatoms selected from S or O. Also disclosed are methods of inhibiting farnesyl protein transferase and methods for treating tumor cells.Type: GrantFiled: February 20, 2001Date of Patent: August 27, 2002Assignee: Schering CorporationInventors: Ronald J. Doll, Carmen Alvarez, Tarik Lalwani, Yi-Tsung Liu
-
Publication number: 20020115738Abstract: This invention relates to functional breakable crosslinkers and polymer networks made of functional breakable crosslinkers. The polymer networks show high selectivity or molecular recognition and are suitable for the use in separation materials and sensors. A representative functional crosslinker is 2,3-Dihydroxy-N,N,N′N′-tetramethyl-N,N′-bis{3-[(2-methylacryloyl)amino]propyl}-1,4-butanediaminium dihalide (“Imprinter-Q”). Imprinter-Q comprises three functional parts: two polymerizable double bonds; two cationic groups; and a 1,2-glycol link between the cationic groups that is easily cleavable. Imprinter-Q can be polymerized with other polymerizable monomers and cross-linkers to obtain polymer networks. After breaking the 1,2-glycol bond, the polymer network has receptor sites that present high affinity for divalent anionic molecules or ions.Type: ApplicationFiled: February 6, 2002Publication date: August 22, 2002Inventors: Tohei Moritani, Carmen Alvarez-Lorenzo
-
Publication number: 20020103207Abstract: Disclosed are compounds of the formula: 1Type: ApplicationFiled: December 20, 2001Publication date: August 1, 2002Inventors: Arthur G. Taveras, Ronald J. Doll, Alan B. Cooper, Johan A. Ferreira, Timothy Guzi, Alan K. Mallams, Dinanath F. Rane, Viyyoor M. Girijavallabhan, Adriano Afonso, Cynthia J. Aki, Jianping Chao, Carmen Alvarez, Joseph M. Kelly, Tarik Lalwani, Jagdish A. Desai, James J-S Wang, Jay Weinstein
-
Patent number: 6410541Abstract: Novel compounds of the formula: are disclosed. In Formula 1.0 a represents N or NO, R1 and R3 are halo, R2 and R4 are independently H or halo provided that at least one is H, X is C, CH or N, and R represents a cycloalkyl or a heterocycloalkyl ring that is substitued. Also disclosed are methods of inhibiting farnesyl protein transferase and methods for treating tumor cells.Type: GrantFiled: January 24, 2001Date of Patent: June 25, 2002Assignee: Schering CorporationInventors: Stacy W. Remiszewski, Ronald J. Doll, Carmen Alvarez, Tarik Lalwani